Comprehensive analysis of Nippon India Nifty Pharma ETF (42116) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
Nippon Life India Asset Management Ltd
The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.
A comprehensive at-a-glance view of key mutual fund health indicatorsHover or click any card to view detailed metrics
Weak Returns
High Risk
Low Expense Ratio
Equity Focused
Established Team
Average Quality
Showing 1Y NAV history
Performance across different time periods
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Outperformance vs benchmark
Market exposure level
Fund management costs
Historical performance consistency
Recent performance momentum
Fund manager experience
Risk-adjusted returns
Assets under management
This fund has underperformed its benchmark by 0.08% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Sector | % Assets |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 22.48% |
| Cipla Ltd | Pharmaceuticals | 10.68% |
| Divis Laboratories Ltd | Pharmaceuticals | 10.23% |
| Dr Reddys Laboratories Ltd | Pharmaceuticals | 9.45% |
| Lupin Ltd | Pharmaceuticals | 5.70% |
| Torrent Pharmaceuticals Ltd | Pharmaceuticals | 4.78% |
| Laurus Labs Ltd | Pharmaceuticals | 4.18% |
| Glenmark Pharmaceuticals Ltd | Pharmaceuticals | 3.93% |
| Aurobindo Pharma Ltd | Pharmaceuticals | 3.89% |
| Mankind Pharma Ltd | Pharmaceuticals | 3.54% |
Compare against ETFs Fund category average
This comparison shows how the fund performs relative to the ETFs Fund category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in ETFs Fund category
| Fund Name | NAV | 6M | 1Y | 3Y |
|---|---|---|---|---|
| LIC MF Gold ETF | ₹9570.79 | 24.06% | 46.48% | 27.20% |
| Invesco India Gold ETF | ₹9238.74 | 23.73% | 45.60% | 26.79% |
| Invesco India Nifty 50 ETF | ₹2811.48 | 12.60% | -1.13% | 13.24% |
| Quantum Nifty 50 ETF | ₹2698.71 | 12.61% | -1.13% | 13.26% |
| BHARAT Bond ETF - April 2030 | ₹1527.12 | 5.09% | 8.85% | 8.00% |
| BHARAT Bond ETF - April 2031 | ₹1366.45 | 4.92% | 8.82% | 8.02% |
| BHARAT Bond ETF - April 2032 | ₹1281.51 | 4.67% | 8.61% | 8.10% |
| BHARAT Bond ETF - April 2033 | ₹1246.34 | 4.83% | 8.52% | N/A |
| DSP BSE Liquid Rate ETF | ₹1089.15 | 2.72% | 5.88% | N/A |
| Shriram Nifty 1D Rate Liquid ETF | ₹1068.95 | 2.66% | 5.76% | N/A |
A seasoned investment professional with over 4 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.